AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data

AstraZeneca PLC (NASDAQ:AZN) ranks among the best-performing European stocks to invest in. Following the release of Phase 3 trial data for baxdrostat at ESC 2025, Goldman Sachs reaffirmed its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) on September 1. The Phase 3 BaxHTN trial found that baxdrostat reduced seated systolic blood pressure (SBP) in a dose-dependent, placebo-adjusted manner at week 12.

According to safety data, both the 2 mg and 1 mg doses had confirmed rates of moderate to severe hyperkalemia of 1.1%, while the placebo had a rate of 0%. Compared to 1.9% with a placebo, discontinuation owing to adverse reactions occurred at rates of 4.5% for the 2 mg dose and 2.7% for the 1 mg dose.

Management stated during its conference call that baxdrostat did not have any clinically significant drug-drug interactions, which is a significant finding for the treatment’s possible use in clinical trials.

AstraZeneca PLC (NASDAQ:AZN) is a prominent player in the pharmaceutical sector, especially for its work on rare disease and cancer treatments. The company has a strong reputation in the healthcare industry thanks to its history of medical advancements.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.